In the News

Immutep Limited (ASX:IMM, NASDAQ:IMMP), March 10, 2025 – CEO and Executive Director Marc Voigt discusses on Clinical Trials, Regulatory Milestones, and Market Growth

Immutep Limited (ASX:IMM, NASDAQ:IMMP), December 5, 2024 – CEO and Executive Director Marc Voigt shares insights on biotech's focus on leveraging patients' immune systems to fight diseases. Immutep's LAG-3 mechanism helps either upregulate or downregulate the immune response based on whether it's for cancer or autoimmune conditions, respectively

Immutep Limited (ASX:IMM, NASDAQ:IMMP), December 5, 2024 – CEO and Executive Director Marc Voigt talks about companies development and insights on how does it differentiate Immutep in the immunotherapy market and what competitive edge could it bring

Immutep Limited (ASX:IMM, NASDAQ:IMMP), November 30, 2024 – CEO and Executive Director Marc Voigt, joins to discuss the challenges of lung cancer, the evolution of immunotherapy, and the innovative approaches Immutep is taking in cancer treatment

Immutep Limited (ASX:IMM, NASDAQ:IMMP), Finance News Network Interview, November 26, 2024 – CEO and Executive Director Marc Voigt reflects on a year marked by promising clinical trial results and a landmark partnership with Merck. He highlights progress in developing treatments for autoimmune diseases and anticipates milestones for the year ahead

Immutep Limited (ASX:IMM, NASDAQ:IMMP), 19 August 2024 – CEO and Executive Director Marc Voigt discusses progress with the company's IMP761 drug, which is potentially active in more than 90% of autoimmune diseases